Expanding Diagnostic Portfolio Veracyte's launch of the Minimal Residual Disease test and the Decipher Prostate Metastatic Genomic Classifier demonstrates a focus on advancing personalized cancer diagnostics, presenting cross-selling opportunities across oncology specialists and hospitals seeking comprehensive genomic testing solutions.
Strong Industry Presence Participation in major healthcare events like JP Morgan, ASTRO, and ASCO highlights the company's active engagement in the oncology and urology communities, providing avenues for targeted outreach to leading clinicians and institutions interested in innovative diagnostic technologies.
Innovative Technology Use Utilizing a range of tech tools including Veeva Vault and DataDog, Veracyte emphasizes its commitment to cutting-edge data management and analytics, supporting scalable solutions that can be customized for large healthcare systems and research collaborations.
Financial Growth Potential With revenue estimated between 250 and 500 million dollars and significant funding of 120 million, the company shows substantial growth prospects, making it an attractive partner for collaborations, investments, and strategic alliances in the rapidly evolving cancer diagnostics space.
Market Opportunities The company's focus on prostate, bladder, and hormone therapy biomarkers aligns with current market trends toward personalized medicine, indicating opportunities to target urology clinics, cancer treatment centers, and genomics labs seeking innovative diagnostic tools for targeted therapy guidance.
$1B$10B
$500M$1B
$10B
$500M$1B
$500M$1B
$10M$25M
$10B
$500M$1BVeracyte, Inc. uses 8 technology products and services including FloQast, Linkedin Insight Tag, DocuSign CLM, and more. Explore Veracyte, Inc.'s tech stack below.
| Veracyte, Inc. Email Formats | Percentage |
| First.Last@veracyte.com | 59% |
| First@veracyte.com | 35% |
| FLast@veracyte.com | 6% |
Biotechnology ResearchCalifornia, United States501-1000 Employees
Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment.
Company Overview
Media & News
Funding & FinancialsVeracyte, Inc. has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2013 in the amount of $65Mas a initial public offering (IPO).
Veracyte, Inc.'s revenue is estimated to be in the range of $250M$500M
Funding & FinancialsVeracyte, Inc. has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2013 in the amount of $65Mas a initial public offering (IPO).
Veracyte, Inc.'s revenue is estimated to be in the range of $250M$500M
1-888-653-2347 
support@leadiq.com